

# *Rosa damascena* oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial

Vahid Farnia<sup>1</sup>  
 Mehdi Shirzadifar<sup>2</sup>  
 Jalal Shakeri<sup>1</sup>  
 Mansour Rezaei<sup>3</sup>  
 Hafez Bajoghli<sup>4,5</sup>  
 Edith Holsboer-Trachsler<sup>6</sup>  
 Serge Brand<sup>6,7</sup>

<sup>1</sup>Substance Abuse Prevention Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran; <sup>2</sup>Student Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran; <sup>3</sup>Department of Statistics and Epidemiology, Kermanshah University of Medical Sciences, Kermanshah, Iran; <sup>4</sup>Iranian National Center for Addiction Studies, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran; <sup>5</sup>ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom, Thailand; <sup>6</sup>Psychiatric Clinics of the Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the University of Basel, Basel, Switzerland; <sup>7</sup>Sport Science Section, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland

Correspondence: Serge Brand  
 Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the University of Basel, Wilhelm Klein-Strasse 27, 4012 Basel, Switzerland  
 Tel +41 61 325 51 14  
 Fax +41 61 325 55 13  
 Email serge.brand@upkbs.ch

**Background:** A substantial disadvantage of psychopharmacological treatment of major depressive disorder (MDD) with selective serotonin-reuptake inhibitors (SSRIs) is the impact on sexual dysfunction. The aim of the present study was to investigate whether the oil of *Rosa damascena* can have a positive influence on SSRI-induced sexual dysfunction (SSRI-I SD) of male patients who are suffering from MDD and are being treated with SSRIs.

**Method:** In a double-blind, randomized, and placebo-controlled clinical trial, a total of 60 male patients treated with an SSRI and suffering from MDD (mean age =32 years) and SSRI-I SD were randomly assigned to take either verum (*R. damascena* oil) or a placebo. Patients completed self-ratings of depression and sexual function at baseline, at 4 weeks later, and at the end of the study, 8 weeks after it started.

**Results:** Over time, sexual dysfunction improved more in the verum group than in the control group. Improvements were observed in the verum group from week 4 to week 8. Self-rated symptoms of depression reduced over time in both groups, but did so more so in the verum group than in the control group.

**Conclusion:** This double-blind, randomized, and placebo-controlled clinical trial showed that the administration of *R. damascena* oil ameliorates sexual dysfunction in male patients suffering from both MDD and SSRI-I SD. Further, the symptoms of depression reduced as sexual dysfunction improved.

**Keywords:** major depressive disorder, *Rosa damascena* oil, sexual dysfunction, selective serotonin-reuptake inhibitors, SSRI-induced sexual dysfunction

## Introduction

Among psychiatric disorders, major depressive disorders (MDDs) merit particular attention because they are among the most prevalent lifetime psychiatric disorders.<sup>1</sup> Not surprisingly, Murray and Lopez, on the basis of data obtained by using the Disability-Adjusted-Life-Years instrument to assess “the sum [of the] years lost due to premature mortality and years lived with disability adjusted for severity”,<sup>2</sup> estimated that MDD will be the third leading cause of burden worldwide by 2020, with chronic lifelong risk for recurrent relapse, high morbidity, comorbidity, and mortality.<sup>1</sup> The core symptom of MDD is the loss of interests and pleasure in activities that were otherwise interesting and pleasant to the patient. This holds particularly true for sexual function. Not surprisingly, patients suffering from MDD report higher rates of sexual dysfunction than do members of a healthy population.<sup>3–7</sup> Accordingly, sexual dysfunction is very often observed among patients suffering from MDD.

There are several options for the treatment of MDD. These include psychotherapy,<sup>8,9</sup> physical activity,<sup>1-13</sup> electroconvulsive therapy,<sup>14,15</sup> and psychopharmacotherapy (antidepressants).<sup>16</sup> In this paper, we focus on the psychopharmacological treatment of MDD.

The explanation for the occurrence of MDD in terms of monoamine deficiency (depletion of serotonin, norepinephrine, and dopamine in the central nervous system)<sup>17</sup> argues for treatment with antidepressants (selective serotonin-reuptake inhibitors [SSRIs], selective serotonin-norepinephrine reuptake inhibitors, noradrenergic and specific serotonergic antidepressants, and serotonin antagonist reuptake inhibitors) that should increase monoamine levels.<sup>18,19</sup> However, several studies indicate that the efficacy of antidepressants is limited; a therapeutic effect is observed at most in 70% of patients suffering from MDD<sup>20</sup> with maximum adherence of 50% 4 weeks after starting treatment.<sup>21</sup> This is probably due to the 2-week or greater time lag for antidepressant to take effect,<sup>20</sup> and is probably also due to various adverse side effects such as weight gain, dry mouth, and sexual dysfunction.<sup>22</sup>

This last side effect, SSRI-induced sexual dysfunction (SSRI-I SD), is considered one of its most disturbing and disruptive side effects.<sup>23-25</sup> Indeed, SSRIs can have a negative impact on any or on all phases of the sexual cycle by causing a decreased libido, an impairment in arousal, and erectile dysfunction; SSRIs are most commonly associated with delayed ejaculation and absent or delayed orgasm.<sup>26</sup> On the basis of a meta-analysis of 31 studies, including a total of 10,130 patients, Serretti and Chiesa<sup>27</sup> concluded that the total rate of sexual dysfunction associated with SSRIs ranged from 25.8% to 80.3% and was significantly higher than the placebo rate of 14.2%. More specifically, Clark et al<sup>24</sup> reported that the SSRIs citalopram, fluoxetine, paroxetine, and sertraline and the SNRI venlafaxine were associated with significantly greater rates (70%–80%) of reported total sexual dysfunction, including negative impacts on desire, arousal, and orgasm, than was the placebo. In this regard, Garlehner et al<sup>28</sup> found that paroxetine, citalopram, and venlafaxine, when compared with other antidepressants (fluoxetine, fluvoxamine, nefazodone, sertraline), were associated with a higher rates of reported sexual dysfunction, such as complaints of erectile dysfunction in men and decreased vaginal lubrication in women. In addition, citalopram was associated with reduced sperm quality.<sup>29</sup>

How can SSRI-I SD be explained? In the absence of a conclusive neurophysiological rationale, the following hypotheses are advanced: 1) whereas sexual dysfunction

occurs through several brain pathways, it is assumed that at least one pathway that involves increases in serotonin (5-HT) leads to an inhibition of the ejaculatory reflex by serotonergic neurotransmission<sup>30</sup> and stimulation of post-synaptic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors;<sup>31,32</sup> 2) decreases in the release of dopamine and norepinephrine from the substantia nigra have been observed;<sup>31,32</sup> 3) the inhibition of nitric oxide synthase has been observed;<sup>33</sup> 4) increases in corticolimbic 5-HT levels seem to be strongly associated with reductions in sexual desire, ejaculation, and orgasm.<sup>34,35</sup> It is therefore perhaps unsurprising that sexual dysfunction is observable in 30%–80% of patients after they begin taking SSRIs.<sup>23,24,27,35,36</sup> Again unsurprisingly, sexual dysfunction seems to be one of the main reasons for discontinuing the intake of SSRIs,<sup>37-39</sup> a pattern observed in up to 90% of patients treated with SSRIs.<sup>40</sup> Therefore, it is important to identify strategies that can alleviate SSRI-I SD.<sup>25,37,38,40</sup>

SSRI-I SD is regarded as such a serious disability probably because for humans, sexual activity and sexual intimacy may serve at least four distinct goals: 1) exploring one's partner's values; 2) reproduction; 3) pair-bonding and pair stabilization;<sup>41</sup> and 4) joy<sup>42-45</sup> or quality of life.<sup>25,45</sup> Among humans, sexual activity within couples usually signifies exclusivity, intimacy, and bond-reinforcing behavior.<sup>41</sup> The sexual activity and sexual intercourse in heterosexual couples can occur under many different conditions: 1) before and after the female's fertile phase (ovulation); 2) during pregnancy; and 3) in females, during post-menopausal stage, thus indicating that, for heterosexual couples, sexual intercourse must serve needs beyond mere reproduction. Further, unlike with bonobos and chimpanzees, who belong to the two species closest to humans and who are sexually active in the presence and sight of other group members, humans, in all cultures and regardless of sexual orientation, engage in sexual relations in private and beyond the view of others; these practices further reinforce exclusive intimacy between partners. Given the exclusivity of sexual activity and its importance to bonding and bonding quality, it is not surprising its impairment is regarded as distressing and disturbing both for the individual and for couple-related quality of life. This holds particularly true for patients suffering from MDD, even during the recovery phase. For example, Clayton et al<sup>25</sup> reported that among patients suffering from MDD, the use of SSRIs was associated with sexual dysfunction and hence had further implications for compliance and distress for the patient and her or his sexual satisfaction.

Overall, the evidence strongly supports the view that among humans, sexual activity has importance beyond mere

reproduction, that it is seriously impaired during MDD, and that the most disturbing side effect of SSRI treatment is SSRI-I SD.

Recommended treatments of SSRI-I SD involve commercially available medications such as sildenafil (Viagra®),<sup>46,47</sup> tadalafil (Cialis®),<sup>47</sup> mianserin,<sup>48</sup> and bupropion.<sup>49</sup> Further, several case reports have been published that focus on the use of antidotes such as cyproheptadine and on augmenting agents including ginkgo biloba, sildenafil, tadalafil, amantadine, bethanechol, bromocriptine, bupropion, dextroamphetamine, granisetron, loratadine, methylphenidate, mianserin, mirtazapine, nefazodone, neostigmine, pemoline, pramipexole, ropinirole, trazodone, vardenafil, and yohimbine. (Extensive reviews are provided by Segraves and Balon<sup>50</sup> and by Balon alone).<sup>35</sup> However, Nurnberg<sup>40</sup> concludes that:

...despite several thousand published reports on treatment modalities based on heuristic post hoc hypotheses of central serotonin inhibition and those involving agonist, antagonist, partial agonist, switching, augmentation, and waiting management approaches, no evidence-based data are available to support those treatment modalities, leaving patients exposed to random pharmacology.

Moreover, to the best of our knowledge, there is no US Food and Drug Administration (FDA)-approved pharmacological treatment for SSRI-I SD, and there is a shortage of randomized, placebo-controlled, and double-blind clinical trials of potential treatments. To address the latter issue, the aim of the present study was to conduct a double-blind, randomized, and placebo-controlled clinical trial examining the effect of *R. damascena* oil, a herbal agent, on SSRI-I SD among male patients suffering from MDD.

In the context of more traditional treatments based on phytopharmaca, the oil of *R. damascena* is particularly worthy of attention because within the long history of Persian medicine, *R. damascena* has been well known for its positive effects on mood, on a broad range of illnesses and diseases, and, most importantly, on sexual dysfunction.<sup>51</sup> *R. damascena* is a hybrid rose species predominantly grown in Iran, Turkey, and Bulgaria to produce rose oil and rose water to be used in perfume and in the cosmetic and food industries. The cultivation and consumption of *R. damascena* in Iran has a long history, and Iran is one of its origins.<sup>52</sup> It is believed that the crude distillation of roses for the oil originated in Persia in the late 7th century AD and spread to the provinces of the Ottoman Empire in the 14th century. Iran was the main producer of rose oil until the 16th century and exported

it to destinations all around the world.<sup>53,54</sup> The extract has also been found to have medicinal properties. It has shown antimicrobial activity. It also has been reported to protect neurons against amyloid  $\beta$  toxicity, a major pathological component of Alzheimer's disease, and to protect rats against seizures.<sup>55-58</sup> The active components of *R. damascena* are not known. *R. damascena* oil is composed of a large number of volatile organic compounds including various terpenes such as citronellol, heneicosane, and disiloxane.<sup>59</sup> The marc, material left after rose oil is extracted, has significant polyphenol content, including quercetin, myricetin, kaempferol, and gallic acid, though the predominant molecules have been suggested to be glycosides of quercetin and kaempferol.<sup>60</sup> With regard to the effects of *R. damascena* on sexual dysfunction, we currently lack evidence based on double-blind, randomized, and placebo-controlled clinical trials. Accordingly, the aim of this study was to test the hypothesis that the adjuvant administration of *R. damascena* oil has a favorable effect on sexual dysfunction among male patients suffering from MDD and SSRI-I SD.

The following three hypotheses were formulated. First, following Boskabady et al<sup>51</sup> we anticipated the adjuvant administration of *R. damascena* oil would improve sexual dysfunction among male patients suffering from MDD and SSRI-I SD. Second, we expected that the administration of *R. damascena* would alleviate symptoms of depression. Third, we expected that the improvements in symptoms of depression and of sexual dysfunction would be associated.


## Method

### Study design

The study entailed an 8-week, randomized, double-blind, placebo-controlled clinical trial. The entire study was approved by the local ethics committee and conducted in accordance with the ethical standards laid down in the Declaration of Helsinki (trial registration number: IRCT2013100814333N10; <http://www.irct.ir>).

### Procedure and sample

Figure 1 shows the Consolidated Standards of Reporting Trials flowchart for patient sampling. Male patients who were diagnosed with MDD, treated with SSRIs, and complained about sexual dysfunction after commencement of the SSRI regimen were recruited between October 2013 and June 2014 at the Outpatients Clinic of Farabi Hospital, Kermanshah University of Medical Sciences in Kermanshah, Iran. So that only patients suffering from MDD and



**Figure 1** CONSORT diagram showing the flow of participants through each stage.  
**Abbreviations:** n, number of subjects; CONSORT, Consolidated Standards of Reporting Trials.

experiencing sexual dysfunction after starting the SSRI regimen were included, trained professional psychiatrists performed interviews based on the structured clinical interview for psychiatric disorders (Mini International Neuropsychiatric Interview).<sup>61</sup> Eligible patients (number [n]=127) were fully informed about the study aims and procedure and about the confidential nature of data selection and data handling, and all of the patients gave their written informed consent. At that time, all eligible patients were in an acute depressive state according to the *Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)* criteria.<sup>62</sup> Prior to being enrolled in the present study, patients had been treated with and stabilized on an SSRI (standard medication) for at least 6 weeks. The treatment regimen remained unaltered throughout the 8-week duration of the study.

A male patient was included in the study if the following criteria were met: 1) he was suffering from an MDD that was diagnosed by a psychiatrist and was based on the *DSM-5* criteria;<sup>62</sup> 2) he was suffering from SSRI-I SD according to the *DSM-5*; 3) he scored at least 19 points or more on the self-rated depressive symptoms on the Beck Depression Inventory (BDI) and could thus be diagnosed with moderate major depression; 4) he scored 2 points or less for self-rated sexual dysfunction, as assessed via the Brief Sexual Function Inventory (BSFI);<sup>63</sup> 5) he had continuous pharmacological treatment with SSRIs for at least 6 weeks prior to entering the study; and 6) he signed a written informed consent form.

Subjects were excluded if they met any of these criteria: 1) the subject did not meet the inclusion criteria as described

previously; 2) he withdrew from the study; 3) he was taking any medication or drug that may affect sexual function; 4) he had any underlying medical or psychiatric disorder (except MDD) that may interfere with sexual function; or 5) he reported side effects (changes in physical and psychological well-being) related to adjuvant medication (intake of either the verum or the placebo). No side effects were reported at any time during the study.

Of the 127 patients screened, 68 were randomly assigned either to the verum group or to the placebo group. Randomization occurred as follows: 35 blue (for verum) and 35 red (for placebo) chips were put in a ballot box and stirred; patients drew a chip and were then assigned to the corresponding group. Neither the patients nor the hospital staff responsible for the randomization knew the group to which any of the subjects had been assigned. Furthermore, none of the personnel involved in the study knew the group to which any of the patients had been assigned. The principal investigator, Vahid Farnia, was not involved in performing the study.

At baseline, 35 patients were assigned to the verum group and 33 were assigned to the placebo group. The two groups did not differ with respect to age (verum: mean age = 32.45 years, standard deviation = 5.68 years; placebo: mean age = 34.02 years, standard deviation = 6.45 years;  $t(66) = 1.34$ ,  $P = 0.54$ ), symptom severity, or sexual dysfunction (Table 1). At follow-up, five patients dropped out of the verum group, and three dropped out of the placebo group. However, statistical computation was performed with the intention-to-treat algorithm and not with the per-protocol algorithm.

## Medication

Patients took their standard SSRI-medications (duloxetine, escitalopram, venlafaxine, or sertraline). Dosages were individually adapted to patients and kept constant for 6 weeks prior to the start of the study in order to achieve treatment efficacy. Next, patients took either verum or placebo in the morning. The verum dosage was 2 mL/day and contained 17 mg Citronellol of essential oil of *R. damascena* (drops), whereas the placebo consisted of 2 mL/day of an oil–water solution with an identical scent. The verum and placebo flacons were identical in shape, weight, look, and, once opened, scent.

(The verum was based on at least 5.8 mg citronellol in each mL of product; the active ingredients are citronellol, geraniol, nerol, linalool, and phenyl ethyl alcohol. Additional components include linalool, saturated fatty alcohols beta-phenyl-ethyl alcohol, farnesol, terpinene-1-ol-4, acetates of the indicated alcohols, free acids, aldehydes [fatty and aromatic], geraniol, neral, ketones, phenols, phenol esters, hydrocarbons, rose oxide, and stearoptene. The verum was manufactured by Barij Essence Pharmaceutical Company in Kashan, Iran).

## Assessing SSRI-induced sexual dysfunction

To assess SSRI-I SD, after the thorough psychiatric interview, psychiatrists also explored the sexual dysfunctions of each patient before he started the treatment with an SSRI, at least 6 weeks before each patient entered the study, and sexual dysfunction during the study. An SSRI-I SD was diagnosed in accordance with the *DSM-5*;<sup>63</sup> if all other factors were equal, sexual dysfunction emerged with the start of SSRI intake.

**Table 1** Descriptive overview of the sexual dysfunction and depressive symptoms scores each group (verum versus placebo) for each assessment time (baseline, week 4, and week 8)

Group	Assessment times					
	Baseline		Week 4		Week 8	
	Verum	Placebo	Verum	Placebo	Verum	Placebo
<b>N</b>	<b>35</b>	<b>33</b>	<b>35</b>	<b>33</b>	<b>35</b>	<b>33</b>
	<b>M ± SD</b>	<b>M ± SD</b>	<b>M ± SD</b>	<b>M ± SD</b>	<b>M ± SD</b>	<b>M ± SD</b>
Sexual drive	1.8±0.84	1.84±0.63	2.07±0.81	1.88±0.71	2.43±0.98	2.03±0.80
Erections	1.78±0.76	1.94±0.69	1.77±0.72	1.82±0.74	2.49±1.09	2.05±0.81
Ejaculations	1.89±0.79	1.92±0.68	2.01±0.78	1.88±0.72	2.71±1.10	2.20±0.92
Problem assessment	1.79±0.99	1.84±0.63	1.90±0.84	1.86±0.71	2.68±1.07	2.15±0.90
Overall satisfaction	1.71±0.89	1.88±0.64	2.14±0.91	1.90±0.68	2.68±1.11	2.33±1.05
Mean score	1.81±0.78	1.89±0.63	1.98±0.73	1.87±0.68	2.58±1.01	2.16±0.87
Beck Depression Inventory	18.93±5.48	18.45±5.43	–	–	16.03±4.75	18.33±5.30

**Notes:** The verum is from *Rosa damascena*. Week 8 marks the end of the study.

**Abbreviations:** N, number of subjects; M, mean; SD, standard deviation.

## Instruments

### *Self-assessment of depressive symptoms by using the BDI*

Patients completed the BDI,<sup>64</sup> which is a self-report of symptoms of depression. The questionnaire consists of 21 items and covers such areas as depressive mood, loss of appetite, sleep disorders, and suicidal thoughts. Answers are given on 4-point Likert scales with the anchor points 0 (for “as always” or “no change”) and 3 (for “not able anymore” or “dramatic change”) and with higher scores reflecting greater severity of depressive symptoms (Cronbach’s alpha =0.89).

### *Self-assessment of sexual dysfunction by using the BSFI*

The BSFI<sup>63</sup> contains eleven questions that cover five domains of sexual function: 1) sexual drive (two items); 2) erectile function (three items); 3) ejaculatory function (two items); 4) sexual problem assessment (three items); and 5) sexual satisfaction (one item). Answers are given on a 5-point Likert scale with scores ranging from 0 (none, big problem, or no activity) to 4 (always, no problem, or high activity) and with lower mean scores reflecting greater sexual dysfunction (Cronbach’s alpha =0.91).

## Statistical analysis

### Preliminary calculations

To detect possible confounders, Spearman’s correlations were computed between sociodemographic data (age, education, civil status, medication intake, number of children) and indices of sexual dysfunction and depressive symptoms. All correlation coefficients were between  $-0.05$  and  $0.15$  ( $P_s >0.56$ ); accordingly, sociodemographic data were not introduced as possible confounders.

Next, a series of Pearson’s correlations was performed between dimensions of sexual dysfunction and depressive symptoms. Further, a series of analyses of variances (ANOVAs) for repeated measures was performed with the factors time (baseline, 4 weeks, and 8 weeks) and group (verum versus placebo), and with sexual dysfunction areas (sexual drive, erections, ejaculations, problem assessment, overall satisfaction, and overall mean score) as dependent variables. Additionally, another ANOVA was computed with the factors time (baseline, 8 weeks) and group (verum versus placebo), with the dependent variable BDI score, and with Bonferroni–Holm corrections for  $P$ -values. Because of deviations from sphericity, ANOVAs for repeated measures (for the factor time with three values) were performed using Greenhouse–Geisser corrected degrees of freedom, although the original degrees of freedom are reported with the relevant

Greenhouse–Geisser epsilon value ( $\epsilon$ ). For ANOVAs, effect sizes are indicated with the partial eta squared ( $\eta^2$ ), with  $0.059 \geq \eta^2 \geq 0.01$  indicating small (S),  $0.139 \geq \eta^2 \geq 0.06$  indicating medium (M), and  $\eta^2 \geq 0.14$  indicating large (L) effect sizes. All computations were performed as intention-to-treat and the last observation carried forward.

The nominal alpha-level was set at 0.05; post hoc analyses were performed with Bonferroni–Holm corrections of  $P$ -values for multiple testing. Statistical analyses were performed with SPSS® 20.0 (IBM Corporation, Armonk, NY, USA) for Apple MacIntosh®.

## Results

### Sexual dysfunction over time and between verum and placebo groups

Tables 1 and 2 show the descriptive and statistical overview of sexual function levels separately by assessment time (baseline, week 4, and 8 weeks later [at the end of the study]) and group (verum versus placebo).

Sexual function improved significantly over time. Post hoc analyses with Bonferroni–Holm corrections for  $P$ -values showed that sexual dysfunction reduced from week 4 to week 8. All effect sizes were large. No statistically significant differences between the groups were observed.

Significant time  $\times$  group interactions were observed for all sexual function variables. Effect sizes were large. Post hoc analyses with Bonferroni–Holm corrections for  $P$ -values showed that sexual dysfunction was lower in the verum than in the placebo group at week 8. Figure 2 shows the mean values for the two groups over the three time points.

### Depressive symptoms

Patients rated their depressive symptoms via the BDI at baseline and at the end of the study (Tables 1 and 2 and Figure 3). Depressive symptoms declined over time; the significant time  $\times$  group interaction showed that depressive symptoms declined more in the verum group than in the placebo group.

### Correlations between sexual dysfunction and symptoms of depression

Correlating symptoms of depression at baseline and after 8 weeks (the end of the study) with sexual dysfunction showed that symptoms of depression and sexual dysfunction were unrelated (all  $r_s < |0.11|$ ,  $p_s >0.41$ ). When correlations were calculated separately for the verum and placebo group, the following pattern of results was observed: for the verum group, again, symptoms of depression and sexual function

**Table 2** Overview of the inferential statistics for the factors time (baseline, week 4, week 8) and group (verum versus placebo) with sexual function as the dependent variable

Degrees of freedom	Time	Group	Time × group interaction	Greenhouse–Geisser epsilon	Post hoc analyses	
	(2, 132)	(1, 66)	(2, 132)		Time	Group
	F $\eta^2$ (EF)	F $\eta^2$ (EF)	F $\eta^2$ (EF)			
Sexual drive	13.65*** 0.171 (L)	1.23 0.018 (S)	3.98* 0.056 (M)	0.827	W8 > W4, BL	V > PL at W8
Erections	23.04*** 0.259 (L)	0.19 0.003 (S)	9.12** 0.121 (M)	0.793	W8 > W4, BL	V > PL at W8
Ejaculations	30.88*** 0.319 (L)	1.11 0.017 (S)	5.91** 0.078 (M)	0.662	W8 > W4, BL	V > PL at W8
Problem assessment	30.72*** 0.319 (L)	0.96 0.008 (S)	5.56** 0.082 (M)	0.736	W8 > W4, BL	V > PL at W8
Overall satisfaction	30.12*** 0.354 (L)	0.90 0.012 (S)	4.59* 0.065 (M)	0.686	W8 > W4, BL	V > PL at W8
Mean score	34.43*** 0.343 (L)	0.72 0.010 (S)	7.23** 0.100 (M)	0.659	W8 > W4, BL	V > PL at W8
Degrees of freedom	(1, 66)	(1, 66)	(1, 66)			
	F $\eta^2$ (EF)	F $\eta^2$ (EF)	F $\eta^2$ (EF)			
Beck depression inventory	11.82** 0.182 (L)	0.77 0.001 (S)	9.07** 0.131 (M)	1.00	–	–

**Notes:** \* =  $P < 0.05$ ; \*\* =  $P < 0.01$ ; \*\*\* =  $P < 0.001$ . “W8 > W4, BL” indicates that all values at week 8 were statistically higher than the values at week 4 and at baseline. “V > PL at W8” indicates that at week 8, values of the verum group were statistically higher than the values of the placebo group.

**Abbreviations:** EF, effect size; S, small effect size; M, medium effect size; L, large effect size; W8, week 8; W4, week 4; BL, baseline; V, verum; PL, placebo.


were unrelated (all  $r_s < |0.13|$ ,  $p_s > 0.38$ ); for the placebo group, more severe symptoms of depression at baseline predicted greater sexual dysfunction at baseline, and after 4 and 8 weeks ( $r_s > 0.35$ ,  $p_s < 0.05$ ). A greater severity of depression symptoms after 8 weeks was associated with greater sexual dysfunction after weeks 4 and 8 of the study ( $r_s > 0.38$ ,  $p_s < 0.05$ ), but not with sexual dysfunction at baseline.

## Discussion


The key findings of the present study are that among male patients suffering from both MDD and SSRI-I SD while being treated with an SSRI standard medication, adjuvant administration of *R. damascena* oil improved sexual dysfunction after 8 weeks more than the adjuvant administration of the

placebo did. Symptoms of depression decreased in parallel, but not linearly. These results confirm the positive effect of *R. damascena* oil on SSRI-I SD in a double-blind, randomized, and placebo-controlled clinical trial and provide an important contribution to the literature on this condition.

Three hypotheses were formulated. Our first hypothesis was that the administration of *R. damascena* oil would improve sexual dysfunction more than a placebo would, and this theory was fully supported. Accordingly, the present study is a contribution to the current literature because, to the best of our knowledge, for the first time the success of an agent in the treatment of an SSRI-I SD in male patients suffering from MDD was proven in a double-blind, randomized, and placebo-controlled clinical trial.

**Figure 2** Comparison of sexual function between verum and placebo groups.

**Notes:** Over time, sexual dysfunction improved significantly more in the verum (*Rosa damascena* oil) group than in the placebo group. Points are means, and bars are standard errors.

**Figure 3** Comparison of BDI scores between verum and placebo groups.

**Notes:** Over time, symptoms of depression (BDI scores) decreased significantly more in the verum (*Rosa damascena* extract) group than in the placebo group. Points are means, and bars are standard deviations.

**Abbreviation:** BDI, Beck Depression Inventory.

Our second hypothesis was that symptoms of depression would improve with adjuvant administration of *R. damascena* oil, and this was also supported. Symptoms of depression declined in both groups, but the decline was greater in the verum group (Tables 1 and 2 and Figure 3). Thus, we were also able to show that *R. damascena* oil had an adjuvant effect on symptoms of depression. However, the present pattern of results expands on previous findings<sup>51</sup> because the results were based on a double-blind, randomized, and placebo-controlled clinical trial.

Our third hypothesis was that improvements in depressive symptoms would occur in parallel to improvements in sexual dysfunction. This was not fully supported. Whereas a pronounced improvement was observed in depressive symptoms in patients treated with adjuvant *R. damascena* oil, improvements of the same extent were not observed in patients treated with the placebo. More importantly, a significant correlation between symptoms of depression and sexual dysfunction was only observed in the placebo group. Thus, whereas both symptoms of depression and sexual dysfunction are closely associated,<sup>25</sup> *R. damascena* oil seemed to have different effects on symptoms of depression and on sexual dysfunction in the verum group.

This last observation illustrates the primary limitation of the present study: the data available do not shed any light on the neurophysiological mechanisms by which *R. damascena* oil has positive effects on symptoms of either depression or sexual dysfunction. Hence, the following proposals are somewhat speculative; they are not strictly evidence-driven. With regard to improvements in sexual dysfunction, it is possible that agents of *R. damascena* oil have an antagonistic effect on the stimulation of the postsynaptic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors<sup>30–32</sup> and that these agents have an antagonistic effect on the corticolimbic 5-HT receptors, which are responsible for increasing sexual desire, ejaculation, and orgasm.<sup>34,35</sup> Additionally, it is possible that the agents of *R. damascena* agonistically increase the release of dopamine and norepinephrine in the substantia nigra,<sup>31,32</sup> as well as disinhibiting nitric oxide synthase.<sup>33</sup> Further, *R. damascena* oil seems to have an antimicrobial effect, and has been reported to protect neurons against amyloid  $\beta$  toxicity, a major pathological component of Alzheimer's disease, and to protect rats against seizures. More specifically, it is suggested that the agent glycoside quercetin is also responsible for improving neuronal activity, probably by inducing the expression of synaptic proteins synaptotagmin and postsynaptic density protein-95, at least in cultured rat cortical neurons.<sup>65</sup> Likewise, quercetin has been shown to reduce

behavioral deficiencies, restore astrocytes and microglia, and reduce serotonin metabolism in a 3-nitropropionic acid-induced rat model of Huntington's Disease.<sup>66</sup> Last, Merzoug et al<sup>67</sup> reported that quercetin mitigated Adriamycin-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats.

With regard to the glycoside kaempferol, evidence from animal studies has shown an antidepressant and modulating effect on brain-derived neurotrophic factor and  $\beta$  amyloid in the neurons and hippocampus of double TgAD mice.<sup>68</sup>

Overall, research on animal models suggest that both quercetin and kaempferol, two of the main agents of *R. damascena* oil, seem to have beneficial influences on symptoms of depression at the molecular level.

Moreover, we also observe that explaining the occurrence and maintenance of MDD in terms of monoamine deficiency is just one of several putative pathways by which MDD might be explained neurophysiologically and neuroendocrinologically. In this regard, more recently efforts have been made to further investigate the roles of the neuropeptide brain-derived neurotrophic factor on MDD,<sup>10,69,70</sup> on ketamine,<sup>71</sup> and statins.<sup>72–75</sup> With regard to statins, by using a mouse model, Ludka et al<sup>16</sup> observed that after acute atorvastatin treatment, the antidepressant effect seemed to be explained via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway; atorvastatin seemed to inhibit NMDA (*N*-methyl-D-aspartic acid) receptors and NO-cGMP (nitric oxide-cyclic guanosine monophosphate) synthesis, leading to a down-regulation of excitatory processes. On a behavioral level, this down-regulation seems to be reflected in a reduction of symptoms of depression. However, it remains unclear to what extent the new pathways explaining MDD neurophysiologically and neuroendocrinologically may help to better understand the influence of the agents of *R. damascena* oil on both symptoms of depression and sexual dysfunction.

Despite the encouraging results, several limitations should be considered to prevent overgeneralization of the data. First, as we have noted, neither the precise effects of the agents of *R. damascena*, nor their neurophysiological and neuroendocrinological influences on MDD and SSRI-I SD, are well understood. Accordingly, the details of the underlying mechanisms remain, for the present, unresolved. Second, participants were selected and recruited from one study center; therefore, a systematic selection bias cannot be excluded. In this regard, third and most importantly, we cannot say whether an identical pattern of results would also have been observed with female patients. Fourth, the present pattern of results



might have emerged because of other latent but unassessed psychological or physiological variables, which might have biased two or more dimensions in the same direction. Fifth, we relied on patients' self-ratings; this might be considered a limitation with regard to symptoms of depression, although the assessment of sexual function does commonly rely on self-ratings. However, future research should also include experts' ratings of symptoms of depression and global clinical impression. Sixth, other depression-related symptoms, such as cognitive performance and psychosocial interaction, along with traits such as social attractiveness,<sup>41</sup> should be assessed. Seventh, future studies might employ a more fine-grained and broader data collection approach with respect to patients' self-ratings and experts' ratings to allow detection of more subtle psychological changes. Last, given the strong associations between depressive symptoms and sleep, future studies on this topic might also assess sleep patterns.

## Conclusion

Evidence from this double-blind, randomized, and placebo-controlled clinical trial shows that the administration of *R. damascena* oil improved sexual dysfunction in male patients suffering from both MDD and SSRI-I SD.

## Acknowledgments

The present work is the doctoral thesis of Mehdi Shirzadifar. We thank Gioia Schultheiss for text editing and Nick Emler (University of Surrey, UK) for proofreading the manuscript.

## Disclosure

The authors declare no conflicts of interest in this work.

## References

1. Josefsson T, Lindwall M, Archer T. Physical exercise intervention in depressive disorders: meta-analysis and systematic review. *Scand J Med Sci Sports*. 2014;24(2):259–272.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. *Lancet*. 1997;349(9063):1436–1442.
3. Johannes CB, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. *J Clin Psychiatry*. 2009;70(12):1698–1706.
4. Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. *Curr Med Res Opin*. 2003;19(2):114–124.
5. Angst J. Sexual problems in healthy and depressed persons. *Int Clin Psychopharmacol*. 1998;13(Suppl 6):S1–S4.
6. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. *J Clin Psychopharmacol*. 2009;29(2):157–164.
7. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. *Expert Opin Drug Saf*. 2014;13(10):1361–1374.
8. Grawe K. [Neuropsychotherapy]. *Neuropsychotherapie*. Göttingen: Hogrefe; 2004.
9. Kanfer FH, Reinecker H, Schmelzer D. [Self-management therapy: a textbook for clinical practice]. *Selbstmanagement-Therapie: Ein Lehrbuch für die klinische Praxis*. 5th ed. New York: Springer; 2012.
10. Mota-Pereira J, Silverio J, Carvalho S, Ribeiro JC, Fonte D, Ramos J. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. *J Psychiatr Res*. 2011;45(8):1005–1011.
11. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. *Cochrane Database Syst Rev*. 2013;9:CD004366.
12. Mura G, Moro MF, Patten SB, Carta MG. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. *CNS Spectr*. 2014;19(6):496–508.
13. Stanton R, Happell B, Haymann M, Reaburn P. Exercise interventions for the treatment of affective disorders – research to practice. *Front Psychiatry*. 2014;5:46.
14. Haghghi M, Salehi I, Erfani P, et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. *J Psychiatr Res*. 2013;47:908–915.
15. Kellner CH, Greenberg RM, Murrrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. *Am J Psychiatry*. 2012;169(12):1238–1244.
16. Ludka FK, Zomkowski AD, Cunha MP, et al. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. *Eur Neuropsychopharmacol*. 2013;23(5):400–412.
17. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? *World Psychiatry*. 2010;9(3):155–161.
18. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry, Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. 2013;14(5):334–385.
19. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. *Brain Res Rev*. 2009;61(2):105–123.
20. Castrén E. Is mood chemistry? *Nature Reviews Neuroscience*. 2005;6(3):241–246.
21. Cassano P, Fava M. Depression and public health – an overview. *J Psychosom Res*. 2002;53(4):849–857.
22. Reichenpader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. *Drug Saf*. 2014;37(1):19–31.
23. Graf H, Walter M, Metzger CD, Abler B. Antidepressant-related sexual dysfunction – perspectives from neuroimaging. *Pharmacol Biochem Behav*. 2014;121:138–145.
24. Clark MS, Jansen K, Bresnahan M. Clinical inquiry: How do antidepressants affect sexual function? *J Fam Pract*. 2013;62(11):660–661.
25. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. *Expert Opin Drug Saf*. 2014;13(10):1361–1374.
26. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. *J Clin Psychopharmacol*. 1999;19(1):67–85.
27. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol*. 2009;29(3):259–266.
28. Gartlehner G, Hansen R, Thieda P, et al. *Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: Comparative Effectiveness Review Number 7*. Rockville: Agency for Healthcare Research and Quality. 2007. Available at: [www.effectivehealthcare.ahrq.gov/ehc/products/7/59/Antidepressants\\_Final\\_Report.pdf](http://www.effectivehealthcare.ahrq.gov/ehc/products/7/59/Antidepressants_Final_Report.pdf). Accessed: March 5, 2012.

29. Elnazer HY, Baldwin DS. Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review. *Acta Neuropsychiatr*. 2014;26(2):125–129.
30. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. *Arch Gen Psychiatry*. 1989;46(3):275–284.
31. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. *Int Clin Psychopharmacol*. 2003;18(3):151–156.
32. Kanaly KA, Berman JR. Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction. *Curr Womens Health Rep*. 2002;2(6):409–416.
33. Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. *Persp Psychiatr Care*. 2002;38(3):111–116.
34. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. *J Clin Psychiatry*. 2001;62:10–21.
35. Balon R. SSRI-Associated Sexual Dysfunction. *Am J Psychiatry*. 2006;163(9):1504–1509.
36. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of anti-depressants. *J Clin Psychopharmacol*. 2009;29(2):157–164.
37. Bull SA, Hunkeler EM, Lee JY. Discontinuing or switching selective serotonin-reuptake inhibitors. *Ann Pharmacother*. 2002;36(4):578–584.
38. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. *J Clin Psychiatry*. 2004;65(7):959–965.
39. Maund E, Tendal B, Hróbjartsson A, et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ*. 2014;348:g3510.
40. Nurnberg HG. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. *Drugs Today (Barc)*. 2008;44(2):147–168.
41. Sela Y, Shackelford TK, Pham MN, Euler HA. Do women perform fellatio as a mate retention behavior? *Pers Individ Diff*. 2015;73:61–66.
42. Buss D. *Evolutionary Psychology: The New Science of Mind*. Essex: Pearson; 2013.
43. Diamond J. *The Third Chimpanzee: The Evolution and Future of the Human Animal*. New York: HarperCollins Publisher; 1992.
44. Meston CM, Buss DM. *Why Women Have Sex: Understanding Sexual Motivations from Adventure to Revenge (and Everything in Between)*. New York: Henry Holt and Company; 2009.
45. Miller G. *The Mating Mind: How Sexual Choice Shaped the Evolution of Human Nature*. New York: Random House; 2000.
46. Damis M, Patel Y, Simpson GM. Sildenafil in the treatment of SSRI-induced sexual dysfunction: a pilot study. *Prim Care Companion J Clin Psychiatry*. 1999;1(6):184–187.
47. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. *Cochrane Database Syst Rev*. 2013;5:CD003382.
48. Dolberg OT, Klag E, Gross Y, Schreiber S. Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. *Psychopharmacology*. 2002;161(4):404–407.
49. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraes E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. *J Clin Psychiatry*. 2005;66(7):844–848.
50. Segraves RT, Balon R. *Sexual Pharmacology: Fast Facts*. New York: WW Norton and Company; 2003.
51. Boskabady MH, Shafei MN, Saberi Z, Amini S. Pharmacological effects of rosa damascena. *Iran J Basic Med Sci*. 2011;14(4):295–307.
52. Chevallier A. *The Encyclopedia of Medicinal Plants*. London: Dorling Kindersely; 1996.
53. Rusanov K, Kovacheva N, Vosman B, et al. Microsatellite analysis of Rosa damascena Mill. accessions reveals genetic similarity between genotypes used for rose oil production and old Damask rose varieties. *Theor Appl Genet*. 2005;111(4):804–809.
54. Tabaei-Aghdai SR, Babaei A, Khosh-Khui M, et al. Morphological and oil content variations amongst Damask rose (Rosa damascena Mill.) landraces from different regions of Iran. *Sci Hortic*. 2007;113:44–48.
55. Basim E, Basim H. Antibacterial activity of Rosa damascena essential oil. *Fitoterapia*. 2003;74(4):394–396.
56. Shokouhinejad N, Emameini M, Aligholi M, Jabalameli F. Antimicrobial effect of Rosa damascena oil on selected endodontic pathogens. *Journal of the California Dental Association*. 2010;38(2):123–126.
57. Awale S, Tohda C, Tezuka Y, Miyazaki M, Kadota S. Protective effects of rosa damascena and its active constituent on AB(25–35)-induced neuritic atrophy. *Evid Based Complement Alternat Med*. 2011;149:131042.
58. Ramezani R, Moghimi A, Rakhshandeh H, Ejtehadi H, Kheirabadi M. The effect of Rosa damascena essential oil on the amygdala electrical kindling seizures in rat. *Pak J Biol Sci*. 2008;11(5):746–751.
59. Loghmani-Khouzani H, Sabzi Fini O, Safari J. Essential oil composition of Rosa damascena mill cultivated in central Iran. *Scientia Iranica*. 2007;14(4):316–319.
60. Kumar N, Bhandari P, Singh B, Gupta AP, Kaul VK. Reversed phase-HPLC for rapid determination of polyphenols in flowers of rose species. *J Sep Sci*. 2008;31(2):262–267.
61. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59(Suppl 20):22–33.
62. American Psychiatric Association. *The Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Arlington: American Psychiatric Publishing; 2013.
63. Mykletun A, Dahl AA, O'Leary MP, Fosså SD. Assessment of male sexual function by the Brief Sexual Function Inventory. *BJU Int*. 2006;97(2):316–323.
64. Beck AT. *Beck depression inventory*. Philadelphia: Center for Cognitive Therapy; 1961.
65. Xu SL, Zhu KY, Bi CW, et al. Flavonoids induce the expression of synaptic proteins, synaptotagmin, and postsynaptic density protein-95 in cultured rat cortical neuron. *Planta Med*. 2013;79(18):1710–1714.
66. Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. *CNS Neurosci Ther*. 2014;20(1):10–19.
67. Merzoug S, Toumi ML, Tahraoui A. Quercetin mitigates Adriamycin-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats. *Naunyn Schmiedebergs Arch Pharmacol*. 2014;387(10):921–933.
68. Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y. Antidepressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. *Neuropharmacology*. 2010;58(6):911–920.
69. Mikoteit T, Beck J, Eckert A, et al. High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression. *J Psychopharmacol (Berl)*. 2014;231(15):2955–2965.
70. Giese M, Beck J, Brand S et al. Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. *J Psychiatr Res*. 2014;59:1–7.
71. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. *J Palliat Med*. 2010;13(7):903–908.

72. Haghghi M, Khodakarami S, Jahangard L, et al. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. *J Psychiatr Res.* 2014;58:109–114.
73. Parsaik AK, Singh B, Murad MH, et al. Statins use and risk of depression: a systematic review and meta-analysis. *J Affect Disord.* 2014;160:62–67.
74. Otte C, Zhao S, Whooley MA. Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. *J Clin Psychiatry.* 2012;73(5):610–615.
75. Tuccori M, Montagnani S, Mantarro S, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. *CNS Drugs.* 2014;28(3):249–272.

### Neuropsychiatric Disease and Treatment

Dovepress

### Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS,

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>